Structural and functional neuropathology in transgenic mice with CNS expression of IFN-α

Brain Research

Volumn 835, Issue 1, 1999, Pages 46-61

  Campbell, Iain L ^a   Krucker, Thomas ^a   Steffensen, Scott ^a   Akwa, Yvette ^a   Powell, Henry C ^b   Lane, Thomas ^c   Carr, Daniel J ^d   Gold, Lisa H ^a   Henriksen, Steven J ^a   Siggins, George R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Microbiology   (United States)

Author keywords

Astrocyte; Interferon; Neurologic disorder; Transgenic

Indexed keywords

ALPHA INTERFERON;

ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISCRIMINATION LEARNING; DISEASE ASSOCIATION; ELECTROPHYSIOLOGY; GENE EXPRESSION REGULATION; GLIOSIS; MOUSE; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEIZURE; TRANSGENIC MOUSE;

ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM; ELECTROPHYSIOLOGY; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERFERON-ALPHA; MICE; MICE, TRANSGENIC; NERVOUS SYSTEM DISEASES;

EID: 0033578192     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)01328-1     Document Type: Conference Paper

References (81)

1. Baron S., Tyring S.K., Fleischmann W.R., Coppenhaver D.H., Niesel D.W., Klimpel G.R., Stanton G.J., Hughes T.K. The interferons: mechanisms of action and clinical applications. J. Am. Med. Assoc. 266:1991;1375-1382.
2. Pestka S., Langer J.A., Zoon K.C., Samuel C.E. Interferons and their actions. Annu. Rev. Biochem. 56:1987;727-777.
3. Samuel C.E. Antiviral actions of interferon. Interferon-regulated cellular proteins and their surprisingly selective antiviral activities. Virology. 183:1991;1-11.
4. Lieberman A.P., Pitha P.M., Shin H.S., Shin M.L. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc. Natl. Acad. Sci. USA. 86:1989;6348-6352.
5. Akiyama H., Ikeda K., Katoh M., McGeer E.G., McGeer P.L. Expression of MRP14, 27E10, interferon-α and leukocyte common antigen by reactive microglia in postmortem human brain tissue. J. Neuroimmunol. 50:1994;195-201.
6. Blatteis C.M. Neuromodulative actions of cytokines. Yale J. Biol. Med. 63:1990;133-146.
7. Dafny N. Is interferon-alpha a neuromodulator? Brain Res. Rev. 26:1998;1-15.
8. Weinstock-Guttman B., Ransohoff R.M., Kinkel R.P., Rudick R.A. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann. Neurol. 37:1995;7-15.
9. Bocci V. Central nervous system toxicity of interferons and other cytokines. J. Biol. Regulators Homeostat. Agents. 2:1988;107-118.
10. Tolmie J.L., Shillito P., Hughes-Benzie R., Stephenson J.B.P. The Aicardi-Goutieres syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). J. Med. Genet. 32:1995;881-884.
11. Kumar D., Rittey C., Cameron A.H., Variend S. Recognizable inherited syndrome of progressive central nervous system degeneration and generalized intracranial calcification with overlapping phenotype of the syndrome of Aicardi and Goutieres. Am. J. Med. Genet. 75:1998;508-515.
12. Lebon P., Badoual J., Ponsot G., Goutieres F., Hemeury-Cukier F., Aicardi J. Intrathecal synthesis of interferon-alpha in infants with progressive familial encephalopathy. J. Neurol. Sci. 84:1988;201-208.
13. Akwa Y., Hassett D.E., Eloranta M.-L., Sandberg K., Masliah E., Powell H., Whitton J.L., Bloom F.E.B., Campbell I.L. Transgenic expression of interferon-a in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J. Immunol. 161:1998;5016-5026.
14. Carr D.J., Veress L.A., Noisakran S., Campbell I.L. Astrocyte-targeted expression of IFN-alpha1 protects mice from acute ocular herpes simplex virus type 1 infection. J. Immunol. 161:1998;4859-4865.
15. Mirra S.S., del Rio C. The fine structure of acquired immunodeficiency syndrome encephalopathy. Arch. Pathol. Lab. Med. 113:1989;858-865.
16. Wegiel J., Wisniewski H.M. Tubuloreticular structures in microglial cells, pericytes and endothelial cells in Alzheimer's disease. Acta Neuropathol. 83:1992;653-658.
17. Rho M.B., Wesselingh S., Glass J.D., McArthur J.C., Choi S., Griffin J., Tyor W.R. A potential role for interferon-α in the pathogenesis of HIV-associated dementia. Brain Behav. Immun. 9:1995;366-377.
18. Moss J., Woodrow D.F., Guillon J.C., Gresser I. Tubular aggregates and interferon. Lancet. 2:1982;1277-1278.
19. Moss J., Woodrow D.F., Sloper J.C., Riviere Y., Guillon J.C., Gresser I. Interferon as a cause of endoplasmic reticulum abnormalities within hepatocytes in newborn mice. Br. J. Exp. Pathol. 63:1982;43-49.
20. Grimley P.M., Ray S., Kostianovsky M., Rupp B., Kang Y.-H., Feldman D. Tubuloreticular reorganization of cytomembranes in cells treated with human alpha interferons. Scanning Microscopy. 2:1988;2141-2151.
21. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS. 103:1995;161-179.
22. Hall G.L., Compston A., Scolding N.J. Beta-interferon and multiple sclerosis. Trends Neurosci. 20:1997;63-66.
23. Arnason B. The role of cytokines in multiple sclerosis. Neurology. 45(Suppl. 6):1995;S54-S55.
24. Campbell I.L., Abraham C.R., Masliah E., Kemper P., Inglis J.D., Oldstone M.B.A., Mucke L. Neurologic disease induced in transgenic mice by the cerebral overexpression of interleukin 6. Proc. Natl. Acad. Sci. USA. 90:1993;10061-10065.
25. Chiang C.-S., Powell H.C., Gold L., Samimi A., Campbell I.L. Macrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of interleukin-3 in transgenic mice. J. Clin. Invest. 97:1996;1512-1524.
26. Wyss-Coray T., Borrow P., Brooker M.J., Mucke L. Astroglial overproduction of TGF-β1 enhances inflammatory central nervous system disease in transgenic mice. J. Neuroimmunol. 77:1997;45-50.
27. Kuriyama K., Hori T., Mori T., Nakashima T. Actions of interferon alpha and interleukin-1 beta on the glucose-responsive neurons in the ventromedial hypothalamus. Brain Res. Bull. 24:1990;803-810.
28. Saphier D., Kidron D., Ovadia H., Trainin N., Pecht M., Burstein Y., Abramsky O. Neurophysiological changes in the brain following central administration of immunomodulatory factors. Isr. J. Med. Sci. 24:1988;261-263.
29. Nakashima T., Hori T., Kuriyama K., Kiyohara T. Naloxone blocks the interferon-α induced changes in hypothalamic neuronal activity. Neurosci. Lett. 82:1987;332-336.
30. Adams F., Quesada J., Gutterman J. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. J. Am. Med. Assoc. 252:1984;938-941.
31. Meyers C.A., Scheibel R.S., Forman A.D. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology. 41:1991;672-676.
32. Dafny N. Interferon modifies EEG and EEG-like activity recorded from sensory, motor, and limbic system structures in freely behaving rats. Neurotoxicology. 4:1983;235-240.
33. Birmanns B., Saphier D., Abramsky O. Alpha-interferon modifies cortical EEG activity: dose-dependence and antagonism by naloxone. J. Neurol. Sci. 100:1990;22-26.
34. Dafny N., Lee J.R., Dougherty P.M. Immune response products alter CNS activity: interferon modulates central opioid functions. J. Neurosci. Res. 19:1988;130-139.
35. Krucker T., Toggas S.M., Mucke L., Siggins G.R. Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short- and long-term potentiation in CA1 hippocampus. Neuroscience. 83:1998;691-700.
36. Reyes-Vazquez C., Prieto-Gomez B., Georgiades J.A., Dafny N. Alpha and gamma interferons' effects on cortical and hippocampal neurons: microiontophoretic application and single cell recording. Int. J. Neurosci. 25:1984;113-121.
37. Reyes-Vazquez C., Prieto-Gomez B., Dafny N. Alpha-interferon suppresses food intake and neuronal activity of the lateral hypothalamus. Neuropharmacology. 33:1994;1545-1552.
38. Reyes-Vazquez C., Mendoza-Fernandez V., Herrera-Ruiz M., Dafny N. Interferon modulates glucose-sensitive neurons in the hypothalamus. Exp. Brain Res. 116:1997;519-524.
39. Muller M., Fontana A., Zbinden G., Gahwiler B.H. Effects of interferons and hydrogen peroxide on CA3 pyramidal cells in rat hippocampal slice cultures. Brain Res. 619:1993;157-162.
40. Tancredi V., D'Arcangelo G., Grassi F., Tarroni P., Palmieri G., Santoni A., Eusebi F. Tumor necrosis factor alters synaptic transmission in rat hippocampal slices. Neurosci. Lett. 146:1992;176-178.
41. D'Arcangelo G., Grassi F., Ragozzino D., Santoni A., Tancredi V., Eusebi F. Interferon inhibits synaptic potentiation in rat hippocampus. Brain Res. 564:1991;245-248.
42. Zeise M.L., Madamba S., Siggins G.R. Interleukin-1 beta increases synaptic inhibition in rat hippocampal pyramidal neurons in vitro. Regul. Pept. 39:1992;1-7.
43. Miller L.G., Galpern W.R., Dunlap K., Dinarello C.A., Turner T.J. Interleukin-1 augments gamma-aminobutyric acidA receptor function in brain. Mol. Pharmacol. 39:1991;105-108.
44. Korn S.J., Giacchino J.L., Chamberlin N.L., Dingledine R. Epileptiform burst activity induced by potassium in the hippocampus and its regulation by GABA-mediated inhibition. J. Neurophysiol. 57:1987;325-340.
45. M.K. Tallent, G.R. Siggins, Somatostatin acts in CA1 and CA3 to reduce hippocampal epileptiform activity, J. Neurophysiol. in press (1999).
46. McNaughton B.L. Long-term synaptic enhancement and short-term potentiation in rat fascia dentata act through different mechanisms. J. Physiol. 324:1982;249-262.
47. Muller D., Lynch G. Evidence that changes in presynaptic calcium currents are not responsible for long-term potentiation in hippocampus. Brain Res. 479:1989;290-299.
48. Wu L.G., Saggau P. Presynaptic calcium is increased during normal synaptic transmission and paired-pulse facilitation, but not in long-term potentiation in area CA1 of hippocampus. J. Neurosci. 14:1994;645-654.
49. Bliss T., Collingridge G.L. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature. 361:1993;31-39.
50. Malinow R., Miller J.P. Postsynaptic hyperpolarization during conditioning reversibly blocks induction of long-term potentiation. Nature. 320:1986;529-530.
51. D.O. Hebb, The Organization of Behavior: A Neuropsychological Theory, Wiley, New York, 1949.
52. Morris R.G.M., Anderson E., Lynch G.S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 359:1986;774-776.
53. Silva A.J., Stevens C.F., Tonegawa S., Wang Y. Deficient hippocampal long-term potentiation in α-calcium-calmodulin kinase II mutant mice. Science. 257:1992;201-206.
54. Bellinger F., Madamba S., Siggins G. Interleukin 1 beta inhibits synaptic strength and long-term potentiation in the rat CA1 hippocampus. Brain Res. 628:1993;227-234.
55. Bellinger F.P., Madamba S.G., Campbell I.L., Siggins G. Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci. Lett. 198:1995;95-98.
56. Katsuki H., Nakai S., Hirai Y., Akaji K., Kiso Y., Satoh M. Interleukin-1 beta inhibits long-term potentiation in the CA3 region of mouse hippocampal slices. Eur J Pharmacol. 181:1990;323-326.
57. Li A.-J., Katafuchi T., Oda S., Hori T., Oomura Y. Interleukin-6 inhibits long-term potentiation in rat hippocampal slices. Brain Res. 748:1997;30-38.
58. Andersen P., Eccles J.C., Loyning Y. Location of presynaptic inhibitory synapses on hippocampus pyramids. J. Neurophysiol. 27:1964;592-607.
59. Andersen P., Eccles J.C., Loyning Y. Pathway of postsynaptic inhibition in the hippocampus. J. Neurophysiol. 27:1964;608-619.
60. Alger B.E., Nicoll R.A. Feed-forward dendritic inhibition in rat hippocampal pyramidal cells studied in vitro. J. Physiol. (London). 328:1982;105-123.
61. Dingledine R., Korn S.J. Gamma-aminobutyric acid reuptake and the termination of inhibitory synaptic potentials in the rat hippocampal slice. J. Physiol. (London). 366:1985;387-409.
62. Schwartzkroin P.A., Scharfman H.E., Sloviter R.S. Similarities in circuitry between Ammon's horn and dentate gyrus: local interactions and parallel processing. Prog. Brain Res. 83:1990;269-286.
63. Steffensen S.C., Campbell I.L., Henriksen S.J. Site-specific hippocampal pathophysiology due to cerebral overexpression of interleukin-6 in transgenic mice. Brain Res. 652:1994;149-153.
64. Shute C.C.D., Lewis P.R. Cholinesterase-containing systems of the brain of the rat. Nature. 199:1963;1160-1164.
65. Mosko S., Lynch G., Cotman C.W. The distribution of septal projections to the hippocampus of the rat. J. Comp. Neurol. 152:1973;163-174.
66. Swanson L.W., Cowan W.M. The connections of the septal region in the rat. J. Comp. Neurol. 186:1979;621-656.
67. Buzsaki G., Ponomareff G.L., Bayardo F., Ruiz R., Gage F.H. Neuronal activity in the subcortically denervated hippocampus: A chronic model for epilepsy. Neuroscience. 28:1989;527-538.
68. Lahtinen H., Miettinen R., Ylinen A., Halonen T., Riekkinen P.J. Biochemical and morphological changes in the rat hippocampus following transection of the fimbria-fornix. Brain Res. Bull. 31:1993;311-318.
69. Segall M., Crnic L. An animal model for the behavioral effects of interferon. Behav. Neurosci. 104:1990;612-618.
70. Dunn A., Crnic L. Repeated injections of interferon-alpha A/D in Balb/c mice: behavioral effects. Brain Behav. Immunol. 7:1993;104-111.
71. Renault P., Hoofnagle J., Park Y., Mullen K., Peters M., Jones D., Rustgi V., Jones E. Psychiatric complications of long-term interferon alfa therapy. Arch. Intern. Med. 147:1987;1577-1580.
72. Iivanainen M., Laaksonen R., Niemi M., Farkkila M., Bergstrom L., Mattson K., Niiranen A., Cantell K. Memory and psychomotor impairment following high-dose interferon treatment in amyotrophic lateral sclerosis. Acta Neurol. Scand. 72:1985;475-480.
73. Smedley H., Katrak M., Sikora K., Wheeler T. Neurological effects of recombinant human interferon. Br. Med. J. 286:1983;262-264.
74. Heyser C.J., Masliah E., Samimi A., Campbell I.L., Gold L.H. Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin-6 in the brain. Proc. Natl. Acad. Sci. USA. 94:1997;1500-1505.
75. Brot M.D., Rall G.F., Oldstone M.B.A., Koob G.F., Gold L.H. Deficits in discriminated learning remain despite clearance of long-term persistent viral infection in mice. J. Neurovirol. 3:1997;265-273.
76. de la Torre J., Mallory M., Brot M., Gold L., Koob G., Oldstone M., Masliah E. Viral persistence in neurons alters synaptic plasticity and cognitive functions without destruction of brain cells. Virology. 220:1996;508-515.
77. Pavol M., Meyers C., Rexer J., Valentine A., Mattis P., Talpaz M. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology. 45:1995;947-950.
78. Segall M., Crnic L. A test of conditioned taste aversion with mouse interferon-alpha. Brain Behav. Immunol. 4:1990;223-231.
79. Black D.N., Watters G.V., Andermann E., Dumont C., Kabay M.E., Kaplan P., Meagher-Villemure K., Michaud J., O'Gorman G., Reece E., Tsoukas C., Wainberg M.A. Encephalitis among Cree children in Northern Quebec. Ann. Neurol. 24:1988;483-489.
80. Dussaix E., Lebon P., Ponsot G., Huault G., Tardieu M. Intrathecal sythesis of different alpha-interferons in patients with various neurological diseases. Acta Neurol. Scand. 7:1985;504-509.
81. Asensio V.C., Kincaid C., Campbell I.L. Chemokines and the inflammatory response to viral infection in the central nervous system with a focus on lymphocytic choriomeningitis virus. J. Neurovirol. 5:1999;65-75.